Zacks Investment Management trimmed its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 11.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 254,662 shares of the biotechnology company's stock after selling 33,347 shares during the period. Zacks Investment Management owned 0.11% of ADMA Biologics worth $4,367,000 as of its most recent SEC filing.
Other hedge funds also recently modified their holdings of the company. Lord Abbett & CO. LLC bought a new stake in ADMA Biologics during the third quarter valued at about $61,858,000. Raymond James Financial Inc. acquired a new stake in ADMA Biologics in the 4th quarter valued at approximately $19,076,000. EWG Elevate Inc. bought a new position in ADMA Biologics in the 4th quarter worth approximately $480,000. Allspring Global Investments Holdings LLC lifted its holdings in shares of ADMA Biologics by 1,144.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company's stock worth $51,016,000 after buying an additional 2,613,482 shares during the last quarter. Finally, Veracity Capital LLC boosted its position in shares of ADMA Biologics by 117.0% in the fourth quarter. Veracity Capital LLC now owns 46,415 shares of the biotechnology company's stock valued at $796,000 after acquiring an additional 25,030 shares during the period. Institutional investors and hedge funds own 75.68% of the company's stock.
ADMA Biologics Trading Down 7.8 %
NASDAQ:ADMA traded down $1.67 on Monday, hitting $19.64. 5,781,097 shares of the stock were exchanged, compared to its average volume of 3,625,664. The stock has a market capitalization of $4.64 billion, a price-to-earnings ratio of 70.14 and a beta of 0.53. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics, Inc. has a 52 week low of $6.19 and a 52 week high of $23.64. The company's 50-day moving average price is $18.26 and its 200 day moving average price is $18.21.
Wall Street Analyst Weigh In
Separately, Cantor Fitzgerald restated an "overweight" rating and set a $25.00 price objective on shares of ADMA Biologics in a report on Tuesday, March 4th.
Read Our Latest Report on ADMA Biologics
About ADMA Biologics
(
Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Read More
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
